Nexalin Technology (NXL) Revenue Growth (1y) (2022 - 2026)
Nexalin Technology (NXL) Revenue Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 7.78% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 2.63% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 9.86% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 11.58% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 16.70% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 15.05% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 7.41% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 6.08% |
| 10 | Nexalin Technology | 9.07 Mn | 6.36 Mn | 13,133.00 | -63.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.55% |
| Dec 31, 2025 | 532.46% |
| Sep 30, 2025 | -49.63% |
| Jun 30, 2025 | 163.00% |
| Mar 31, 2025 | -47.87% |
| Dec 31, 2024 | 32.35% |
| Sep 30, 2024 | 49.43% |
| Jun 30, 2024 | -24.48% |
| Mar 31, 2024 | 157.43% |
| Dec 31, 2023 | -46.55% |
| Sep 30, 2023 | -95.58% |
| Jun 30, 2023 | -91.42% |
| Mar 31, 2023 | -90.55% |
| Dec 31, 2022 | 60.11% |
| Sep 30, 2022 | 874.31% |